Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
Financial Results:
Suven Life Sciences Ltd reported Revenues for Q2FY24 of ₹3.00 Crores down from ₹4.00 Crore year on year, a fall of 25.0%.
Total Expenses for Q2FY24 of ₹29.00 Crores up from ₹28.00 Crores year on year, a rise of 3.57%.
Consolidated Net Profit of -₹13.00 Crores from -₹23.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹0.58, from -₹1.06 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.